Hints and tips:
Related Special Reports
...Ark, which counts Tesla and Zoom Video Communications among its largest holdings, is up 12 per cent since the start of the year....
...Obviously, this flavour of defence is par for the course in antitrust, but we were curious whether Crevoiserat has been serving a similarly smol bean line to investors....
...Teresa Graham, chief of Roche’s pharmaceutical division, said more patients suffered from diseases of the immune system than from cancer, and the current drugs did not serve them well....
...In May, the Pharmaceutical Supply Chain Initiative, a lobby set up by large pharmaceutical companies, said its members should stop sourcing blood from the two Asian horseshoe crab species most at risk....
...their par value....
...The valuation of $900mn marks a new high for F1 and puts it on a par with some big European football deals....
...Spirax-Sarco, a top engineering group, and AstraZeneca, the pharmaceuticals producer, sit at more than £90 for a single share....
...The transaction left GSK and Pfizer holding 13.5 per cent and 32 per cent of the shares, respectively....
...The gradient of spread changes on the stack reflects the market’s take on the coupon distribution of SVB’s HTM holdings....
...It also generated excitement across the pharmaceutical industry, which is enticed by the prospect of selling medicines to the more than 50mn people worldwide who suffer from the disease....
...PMI chief executive Jacek Olczak told the Financial Times that Vectura’s sales had suffered because of the reluctance of pharmaceutical partners to work with the company....
...Some analysts say it is Illumina rather than Grail that faces the biggest near-term risks given the terms of a holding agreement imposed by EU regulators on the company before they issue a final divestment...
...But they warn that the ruling casts a shadow over the company as it seeks to remodel itself as an innovator in the pharmaceutical and medical devices sectors....
...It says it now puts antibiotic resistance on a par with climate change and biodiversity loss as a systemic risk to strong and stable markets....
...It was a filing made by an entity named FCM BBBY Holdings, LLC which listed its address as a nondescript Wyoming office building....
...Meanwhile, real estate developers and investors have latched on to life sciences as the rise of working from home threatens financial returns from their office holdings....
...Tishman Speyer, one of New York’s largest commercial property developers, had previously secured pharmaceuticals company Pfizer as its anchor tenant for the Spiral....
...The measures represent “the most crucial pivot since Beijing significantly tightened financing of the property sector,” economists at Nomura Holdings Inc. wrote Monday in a note....
...The following day, Cohen disclosed plans to also sell his holding of roughly 12 per cent, and the shares plunged. By the end of the week they were worth just $11....
...Berkshire’s securities filing on Monday showed that it continued to sell down investments in a handful of pharmaceutical companies in the final months of 2021....
...The expected average size of the deal is between $1.8m and $4.3m, with internal rate of return expected to be on par with buyout funds at about 20 per cent, Nomura said....
...Michael Sklar, develops “nonstandard trial designs”, which seems to basically use maths to speed up the process of developing pharmaceutical studies....
...“Pharmaceutical companies have a duty to do their utmost on this but unfortunately we see that they are lagging behind....
...The cuts place the MBS ETF’s price on par with its biggest competitors....
...These are early data but still very reassuring that our vaccines are holding up for the purpose they were designed for — to protect against severe disease and death.”...
International Edition